Print
contact ussite map
Juvaris Beotherapeutics, Inc.

Overview

Juvaris BioTherapeutics, Inc. is developing novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.

The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.

Adjuvanted Vaccine Development

  • JVRS-100 is being developed as an adjuvant to improve the effectiveness of available vaccines and to develop novel vaccines against otherwise untreatable diseases.
  • Adjuvants enhance the effect of vaccines by increasing the quantity and quality of the immune response and reducing the amount of antigen required in the vaccine.

Immunotherapeutic Development

  • JVRS-100 is being developed as an immunotherapeutic to treat infectious disease and cancer.
  • JVRS-100 has been shown to induce significant innate immunity resulting in anti-viral, anti-bacterial and anti-cancer effects.

Juvaris has completed two major fundraising rounds from leading venture capitalists, including a recently completed Series B financing that comprised of Kleiner Perkins Caufield & Byers, SV Life Sciences and a strategic corporate investor. Juvaris has also obtained substantial research support through grants from the National Institutes of Health and from an array of distinguished academic collaborators. The Company also has a worldwide strategic alliance with Bayer HealthCare AG for the use of its technology in the field of animal health.

^ back to top

© 2014 Juvaris BioTherapeutics.